President Donald Trump unveiled TrumpRx on Thursday night — a direct-to-consumer website that connects patients with drugmakers offering steep discounts on brand-name medications. The platform launched with five pharmaceutical giants on board: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer.
The site doesn't sell drugs directly. It routes patients to drugmakers' own direct-to-consumer platforms or provides discount coupons they can take to a pharmacy. The effect is the same: Americans pay less.
You're going to save a fortune and this is also so good for overall health care.
That was Trump at Thursday's event, where he said millions of Americans would save money through the platform. The numbers back the ambition. Novo Nordisk's Ozempic, the blockbuster diabetes drug, starts at $199 per month on the platform — down from a list price hovering around $1,000. Wegovy injections for obesity: $199 per month, slashed from roughly $1,350. Eli Lilly's Zepbound injection drops to $299 from $1,086. EMD Serono's fertility treatment Gonal-F lands at $168.
These aren't marginal adjustments. They're the kind of price corrections Americans have demanded for years while Washington dithered.
The U.S. prescription drug market is a labyrinth of intermediaries, rebates, and opaque pricing structures that consistently leave patients holding the largest share of the bill. According to the Rand Corp., American prescription drug prices run two to three times higher on average than those in other developed nations — and up to ten times more than in certain countries. Everyone in Washington has known this for decades. The difference now is that someone is taking action.
According to CNBC, the TrumpRx deals are part of a broader "most favored nation" policy that seeks to align U.S. drug prices with the lowest paid abroad. At least 16 drugmakers have negotiated agreements with the administration, including Lilly and Novo, and at least 14 others have agreed to participate on the platform and voluntarily sell certain medicines at a discount to Medicaid patients. Drugs from additional companies will be listed in the coming months.
Bristol Myers Squibb CEO Chris Boerner, who said at a January conference that his company is "aligned with the administration" on the complexity of the U.S. health care system, put the logic plainly:
What we like about these [direct-to-consumer models], where they make sense from a business standpoint, is you're able to circumvent some of that.
"Some of that" is the layers of middlemen who inflate costs between the manufacturer and the patient. Bristol Myers already operates its own direct-to-consumer platform — first offering a cash-pay discount on its blood thinner Eliquis — and plans to eventually link it to TrumpRx. Boerner said the company will examine ways to put additional products on its own platform where it makes sense.
When the pharmaceutical companies themselves are eager to cut out the middlemen, it tells you everything about who benefits from the status quo — and it isn't patients.
Eli Lilly CEO Dave Ricks noted in an interview last week that his company was the first drugmaker to sell obesity treatments directly to patients. TrumpRx, he said, is "taking that and expanding it across the industry" to other medicines.
We're all for that.
That's not a reluctant concession. That's an industry leader recognizing that the direct-to-consumer model works — for business and for patients. Lilly and Novo Nordisk were already offering blockbuster obesity drugs at hefty discounts to cash-paying patients on their own platforms before Thursday's announcement. TrumpRx systematizes what was already proving viable and scales it across the pharmaceutical landscape.
The agreements go further than discount websites. Medicare will begin covering weight-loss treatments for the first time later this year as part of the deals Lilly and Novo struck with the administration. That's a concrete expansion of access for seniors, negotiated not through new bureaucratic mandates but through direct dealmaking with the companies that manufacture the drugs.
The platform's clearest winners are Americans without insurance or with plans that don't cover certain medications — particularly the new generation of obesity drugs that many insurers still refuse to touch. When a month's supply of Wegovy costs $1,350 at list price, and your insurer won't cover it, $199 through TrumpRx isn't a coupon. It's the difference between treatment and going without.
Juliette Cubanski, deputy director of the program on Medicare Policy at KFF, a health policy research organization, acknowledged the potential:
If they're able to get a drug covered by their insurance at a relatively affordable copay, then there's not a great upside to using the TrumpRx website.
Fair enough — but that conditional clause carries a lot of weight. Millions of Americans can't get these drugs covered at a relatively affordable copay. That's the entire point. Cubanski herself acknowledged the platform's potential to expand access to certain drugs at more affordable prices, particularly medicines not widely covered by insurance, such as obesity drugs.
She also noted that people with insurance who buy through direct-to-consumer platforms may not have those purchases count toward their deductible or out-of-pocket maximum. That's a real consideration for insured patients doing the math. But for the uninsured, the underinsured, and those whose plans simply don't cover the drugs they need, TrumpRx represents something the existing system hasn't provided: a straightforward path to lower prices without navigating a bureaucratic maze.
It's worth noting that the discounts are measured against retail list prices — the sticker price that private insurers and government programs often negotiate down through rebates and other mechanisms. Average discounts on brand-name drugs in Medicare Part D already run around 40% of list prices, according to researchers at Georgetown's Medicare Policy Initiative. Discounts in Medicaid exceed 75%, according to a Congressional Budget Office study.
None of that helps the cash-paying patient staring at a pharmacy counter. The rebate system is designed for institutional payers, not individuals. TrumpRx takes the discount that was previously accessible only through layers of negotiation and hands a version of it directly to the consumer. Some doses of Ozempic, for instance, are priced at $350 per month under Novo Nordisk's agreement — less than half its roughly $1,000 monthly list price, with starting doses available at $199. The Wegovy pill comes in at $149 per month for starting doses.
What makes TrumpRx distinctive isn't just the price tags. It's the mechanism. This isn't a government price control. It's not a new entitlement program requiring appropriations battles and regulatory buildout. It's a marketplace — the administration negotiating voluntary deals with private companies that have their own business incentives to participate. The drugmakers sell more product at scale. Patients pay less. The middlemen who've profited from complexity lose leverage.
That model — using the weight of the presidency to broker competitive deals rather than layering on new government infrastructure — is precisely the kind of approach that Washington's permanent class has always dismissed as too simple to work. Too simple, perhaps, because it doesn't require hiring 10,000 new federal employees to administer.
Dozens of other drugs are expected to join the platform, including treatments from Amgen, Merck, and Gilead, though they weren't listed as of Thursday night. If the initial deals deliver real savings at scale, the pressure on holdout manufacturers to participate will build quickly. No CEO wants to explain to shareholders why competitors are moving product through a presidential platform while they're sitting on the sidelines.
The launch is the beginning, not the finish line. The platform's long-term impact depends on how many drugs get listed, how aggressively the administration expands the program, and whether the direct-to-consumer model proves sustainable for drugmakers at these price points. Medicare coverage of weight-loss treatments later this year will be another test—and another win if it passes.
For now, TrumpRx does something Washington rarely manages: it delivers a tangible, immediate benefit that ordinary Americans can use the moment they hear about it. No enrollment period. No means testing. No 400-page regulatory guidance document. A website, a discount, and a path to the pharmacy.
Americans have spent years being told that drug prices are an intractable problem requiring systemic overhaul, blue-ribbon commissions, and decades of incremental reform. On Thursday night, five pharmaceutical companies started selling their products for a fraction of the sticker price through a website on which the president put his name.
Sometimes, the intractable problem just needed someone willing to pick up the phone.
